SAVA vs. ZNTL, IMNM, OPK, TYRA, ETNB, ARQT, CNTA, TNGX, SPRY, and INVA
Should you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Zentalis Pharmaceuticals (ZNTL), Immunome (IMNM), OPKO Health (OPK), Tyra Biosciences (TYRA), 89bio (ETNB), Arcutis Biotherapeutics (ARQT), Centessa Pharmaceuticals (CNTA), Tango Therapeutics (TNGX), ARS Pharmaceuticals (SPRY), and Innoviva (INVA). These companies are all part of the "pharmaceutical preparations" industry.
Cassava Sciences (NASDAQ:SAVA) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.
Cassava Sciences is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
38.1% of Cassava Sciences shares are held by institutional investors. 9.0% of Cassava Sciences shares are held by insiders. Comparatively, 6.1% of Zentalis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Cassava Sciences presently has a consensus price target of $124.00, indicating a potential upside of 455.06%. Zentalis Pharmaceuticals has a consensus price target of $38.57, indicating a potential upside of 248.75%. Given Cassava Sciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Cassava Sciences is more favorable than Zentalis Pharmaceuticals.
In the previous week, Cassava Sciences had 3 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 5 mentions for Cassava Sciences and 2 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 1.13 beat Cassava Sciences' score of 0.11 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.
Cassava Sciences' return on equity of -57.53% beat Zentalis Pharmaceuticals' return on equity.
Cassava Sciences has a beta of -0.45, indicating that its share price is 145% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500.
Cassava Sciences received 44 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. Likewise, 66.20% of users gave Cassava Sciences an outperform vote while only 64.10% of users gave Zentalis Pharmaceuticals an outperform vote.
Summary
Cassava Sciences beats Zentalis Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
Get Cassava Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SAVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cassava Sciences Competitors List
Related Companies and Tools
